MedTrace Logo

Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura

NCT00004920 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2012-07-18

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving cisplatin with raltitrexed is more effective than cisplatin alone for malignant mesothelioma.

PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without raltitrexed in treating patients who have malignant mesothelioma of the pleura.

Conditions

  • Malignant Mesothelioma

Interventions

DRUG

cisplatin

DRUG

raltitrexed

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Jan P. Van Meerbeeck, MD, PhD · University Medical Center Rotterdam at Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2003-01-31

Countries

  • Belgium
  • Canada
  • Egypt
  • France
  • Germany
  • Italy
  • Netherlands
  • Peru
  • Poland
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004920 on ClinicalTrials.gov